Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.

Schizophrenia
Sumitomo and Otsuka have entered a deal of up to $890m centered on psychiatric drugs • Source: Shutterstock

Sumitomo Dainippon Pharma Co., Ltd.’s Sunovion Pharmaceuticals subsidiary and Otsuka Holdings Co., Ltd. both stand to gain from a development and commercialization deal around four central nervous system (CNS) drugs that brings together two major players in psychiatric drugs while also providing two compounds already in late-stage development. In particular, Sumitomo will benefit from Otsuka’s CNS expertise and marketing heft.

Sumitomo and Sunovion, along with Otsuka, announced a deal on 30 September worth up to $890m – including a $270m...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.